Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 1
2007 1
2008 2
2009 3
2010 3
2011 2
2012 2
2013 3
2014 5
2015 2
2016 4
2017 5
2018 6
2019 4
2020 2
2021 7
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial.
Maier HB, Neyazi A, Bundies GL, Meyer-Bockenkamp F, Bleich S, Pathak H, Ziert Y, Neuhaus B, Müller FJ, Pollmann I, Illig T, Mücke S, Müller M, Möller BK, Oeltze-Jafra S, Kacprowski T, Voges J, Müntefering F, Scheiber J, Reif A, Aichholzer M, Reif-Leonhard C, Schmidt-Kassow M, Hegerl U, Reich H, Unterecker S, Weber H, Deckert J, Bössel-Debbert N, Grabe HJ, Lucht M, Frieling H. Maier HB, et al. Among authors: muller m. Trials. 2024 Apr 9;25(1):247. doi: 10.1186/s13063-024-08061-5. Trials. 2024. PMID: 38594753 Free PMC article. Clinical Trial.
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.
Gress C, Vogel-Claussen J, Badorrek P, Müller M, Hohl K, Konietzke M, Litzenburger T, Seibold W, Gupta A, Hohlfeld JM. Gress C, et al. Among authors: muller m. Pulm Pharmacol Ther. 2023 Oct;82:102246. doi: 10.1016/j.pupt.2023.102246. Epub 2023 Aug 9. Pulm Pharmacol Ther. 2023. PMID: 37562641 Clinical Trial.
"Rogue" neutrophil-subset [DEspR+CD11b+/CD66b+] immunotype is an actionable therapeutic target for neutrophilic inflammation-mediated tissue injury - studies in human, macaque and rat LPS-inflammation models.
Carstensen S, Müller M, Tan GLA, Pasion KA, Hohlfeld JM, Herrera VLM, Ruiz-Opazo N. Carstensen S, et al. Among authors: muller m. Front Immunol. 2022 Oct 4;13:1008390. doi: 10.3389/fimmu.2022.1008390. eCollection 2022. Front Immunol. 2022. PMID: 36275710 Free PMC article.
Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.
Herrera VLM, Walkey AJ, Nguyen MQ, Gromisch CM, Mosaddhegi JZ, Gromisch MS, Jundi B, Lukassen S, Carstensen S, Denis R, Belkina AC, Baron RM, Pinilla-Vera M, Muller M, Kimberly WT, Goldstein JN, Lehmann I, Shih AR, Ells R, Levy BD, Rulz-Opazo N. Herrera VLM, et al. Among authors: muller m. Res Sq [Preprint]. 2021 Sep 13:rs.3.rs-846250. doi: 10.21203/rs.3.rs-846250/v1. Res Sq. 2021. PMID: 34545358 Free PMC article. Preprint.
57 results